The pharma major's consolidated net profit jumped 46.55% to Rs 510 crore on 22.47% increase in revenue from operations to Rs 2,338 crore in Q2 FY25 over Q2 FY24.
Total income grew by 22.51% year on year (YoY) to Rs 2,444 crore in the quarter ended 30 September 2024.
Profit before tax for the quarter was at Rs 722 crore, up 53.94% from Rs 469 crore reported in the same period a year ago.
Total expenses stood at Rs 1,722 crore in second quarter of FY25, up 12.84% on YoY basis. Cost of material consumed was at Rs 976 crore (up 37.27% YoY) and employee benefit expenses stood at Rs 304 crore (up 14.29% YoY) during the period under review.
Forex gain for the current quarter amounted to Rs 29 crore as against a gain of Rs 11 crore posted in Q2 FY24.
Also Read
 "National green tribunal, NGT")
 "Modi, Narendra Modi")
 "Modi, Narendra Modi")
 "Atishi marlena, Atishi, Delhi CM")
 "New Delhi, India, air pollution")
On half yearly basis, the companys net profit climbed 33.52% to Rs 940 crore on 20.86% rise in revenue from operations to Rs 4,456 crore in H1 FY25 over H1 FY24.
Forex gain for the six month period amounted to Rs 28 crore as against a gain of Rs 14 crore posted in same period a year ago.
Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients.
Shares of Divis Laboratories declined 0.34% to end at Rs 5,938.15 on Friday, 8 November 2024.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
